Birmingham, West Midlands -- (SBWIRE) -- 12/26/2013 -- Value Penny Stocks issues special report on Idera Pharmaceuticals Inc (NASDAQ: IDRA), American Capital Ltd. (NASDAQ:ACAS), Atossa Genetics Inc (NASDAQ:ATOS), IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI).
Idera Pharmaceuticals Inc (NASDAQ: IDRA) opened its last trade at the price of $3.14. Its closing price was $3.39 after gaining 7.96% for the day. The company traded with the total volume of 1,198,509 shares, while its average trading volume remained 1.36 million shares. The beta of this stock stands at 1.94. Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs).
For How Long IDRA will Fight for Profitability? Read This Trend Analysis report
American Capital Ltd. (NASDAQ:ACAS) percentage change surged 0.78% to close at $15.52 with the total traded volume of 1,193,774 shares, along with average volume of 2.28 million shares. The 52 week range of the stock remained $11.81 - $15.58, while its day lowest price was $15.38. The share price hit the day highest price of $15.58. American Capital, Ltd. is a private equity and venture capital firm specializing in management and employee buyouts, leveraged finance, mezzanine, acquisition, recapitalization, middle market, and growth capital investments.
For How Long ACAS’s Gloss will Attract Investors? Find out via this report
Atossa Genetics Inc (NASDAQ:ATOS) traded on volume of 1,172,551 shares in the last session against average volume of 244,284.00 shares. The company started its trading session with the price of $2.81 and closed at $2.60 by scoring +11.11%. Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States.
Will ATOS Continue To Move Higher? Find Out Here
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) started its last trading session with the price of $3.49 and closed at $3.73 by scoring +9.06%. The stock traded with total volume of 1,150,212 shares, while the average trading volume remained 2.41 million shares. The beta value of this stock stands at 1.25. Day range for the stock was $3.37 - $3.85. Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain.
What IPCI’s Charts Are Signaling for Traders? Find Out Here
About Value Penny Stocks:
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)